Corpus Intelligence IC Memo — INCLINE VILLAGE HOSPITAL 2026-04-26 08:05 UTC
IC Memo — INCLINE VILLAGE HOSPITAL
Investment Committee Memorandum | NV | 4 beds | Grade D | EBITDA uplift $1.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

INCLINE VILLAGE HOSPITAL

CCN 291301 | WASHOE, NV | 4 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

INCLINE VILLAGE HOSPITAL is a 4-bed community hospital in WASHOE, NV with $19.8M in net patient revenue and a 11.0% operating margin. The hospital serves a payer mix of 100.0% Medicare, 0.0% Medicaid, and 0.0% commercial.

Thesis: Turnaround. Our ML models identify $1.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 11.0% to 18.4% (+736bps).

Net Revenue HCRIS$19.8M
Current EBITDA COMPUTED$2.2M
Operating Margin COMPUTED11.0%
Occupancy HCRIS0.1%
Revenue / Bed COMPUTED$5.0M
Net-to-Gross HCRIS52.1%
Distress Probability MLnan%

2. Market Context & Competitive Position

58
NV Hospitals
0.4%
State Median Margin
0
Comparable Hospitals

NV has 58 Medicare-certified hospitals with a median operating margin of 0.4%. The target's margin of 11.0% places it above the state median. Among 0 size-comparable peers (2-8 beds), the median margin is 0.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (2-8), prioritizing same-state peers. 0 hospitals in the comp set.

HospitalStateBedsRevenueMargin
INCLINE VILLAGE HOSPITAL (Target)NV4$19.8M11.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$416K+210bp18mo
Cost to Collect4.5%2.5%$396K+200bp12mo
Denial Rate Reduction12.0%6.5%$392K+198bp12mo
A/R Days Reduction5200.0%3800.0%$241K+122bp9mo
Clean Claim Rate88.0%96.0%$13K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$416K
Cost to Collect
$396K
Denial Rate Reduction
$392K
A/R Days Reduction
$241K
Clean Claim Rate
$13K
Total EBITDA Uplift$1.5M
Current EBITDA$2.2M
+ RCM Uplift+$1.5M
Pro Forma EBITDA$3.6M
Current Margin11.0%
Pro Forma Margin18.4%
WC Released (1x)$759K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$3.4M$29.0M8.63x53.9%
Base (11x exit)10.0x11.0x$3.4M$33.0M9.81x57.9%
Bull Case9.0x11.0x$3.0M$38.9M12.86x66.7%
Bull (12x exit)9.0x12.0x$3.0M$43.3M14.32x70.3%
Bear Case11.0x10.0x$3.7M$20.6M5.58x41.0%
Bear (11x exit)11.0x11.0x$3.7M$23.9M6.46x45.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumHeavy Medicare dependenceMedicare comprises 100.0% of days; rate updates may lag inflation. Mitigant: CDI/CMI lever directly increases Medicare reimbursement
MediumLow occupancyAt 0.1%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 0 hospitals with 2-8 beds
  • Same-state prioritization (n=3)
  • Comp margins: P25=nan% / P50=0.0% / P75=nan%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.